Cerenome, Inc.
CNSYHealthcare|Medical - Pharmaceuticals|US
$0.64
-0.03 (-4.06%)
DCF Value
$2.01
Tangible Book / Share
$0.71
Cash / Share
$1.27
About
Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Stock Price
-84.1%(1Y)
1M
-64.1%
3M
-83.2%
6M
-84.1%
YTD
-84.1%
1Y
-84.1%
3Y
-84.1%
5Y
-84.1%
Pipeline Summary
5 total trials5
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 4Completed: 1
Active Trials (4)
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
NCT07061626Ependymoma
Phase 1Recruiting
Enrollment: 56 participants
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
NCT05460507Glioma
Phase 1Recruiting
Enrollment: 40 participants
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
NCT01906385Glioma
Phase 1Phase 2Recruiting
Enrollment: 55 participants
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
NCT07098806Leptomeningeal Metastasis
Phase 1Phase 2Recruiting
Enrollment: 24 participants
Key Facts
Market Cap$4.9M
Employees28
CEOMarc H. Hedrick
IPO DateAug 3, 2026
Beta1.49
52-Week Range$0.6 – $19
Avg Volume477,500
ExchangeNASDAQ
Websiteplustherapeutics.com
Ownership
Shares Outstanding7.6M
Recent Insider Trades
van Es-Johansson AnOPTION EX.
Oct 1, 2026921 shares
van Es-Johansson AnOPTION EX.
Oct 1, 2026921 shares
Hawkins Richard JOPTION EX.
Oct 1, 2026921 shares
Hawkins Richard JOPTION EX.
Oct 1, 2026921 shares
Sims Andrew John Hugh MacIntyreOPTION EX.
Oct 1, 20261,533 shares
Recent News
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Nov 4, 2026 · globenewswire.com
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Oct 29, 2026 · globenewswire.com
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Oct 27, 2026 · globenewswire.com
New Strong Sell Stocks for October 22nd
Oct 22, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:03 AM